ICBC CREDIT SUISSE ASSET MGT CO LTD CSI BRAND NAME DRUG INDUSTRY IDX ETF CNY
No trades
Key stats
About ICBC CREDIT SUISSE ASSET MGT CO LTD CSI BRAND NAME DRUG INDUSTRY IDX ETF CNY
Home page
Inception date
Feb 9, 2021
Structure
Open-Ended Fund
Replication method
Physical
Dividend treatment
Distributes
Primary advisor
ICBC Credit Suisse Asset Management Co., Ltd.
ISIN
CNE100004FV2
Closely track the underlying index, Tightly track the target and minimize the deviation, and strive to achieve long-term investment returns consistent with the performance of the underlying index.
Classification
Returns
| 1 month | 3 months | Year to date | 1 year | 3 years | 5 years | |
|---|---|---|---|---|---|---|
| Price performance | — | — | — | — | — | — |
| NAV total return | — | — | — | — | — | — |
What's in the fund
Exposure type
Health Technology
Stocks98.60%
Health Technology98.01%
Commercial Services0.59%
Bonds, Cash & Other1.40%
Cash1.40%
Stock breakdown by region
Asia97.87%
Europe2.13%
North America0.00%
Latin America0.00%
Africa0.00%
Middle East0.00%
Oceania0.00%
Top 10 holdings
Dividends
Dividend payout history
Assets under management (AUM)
Fund Flows
Frequently Asked Questions
516060 invests in stocks. The fund's major sectors are Health Technology, with 98.01% stocks, and Commercial Services, with 0.59% of the basket. The assets are mostly located in the Asia region.
516060 top holdings are WuXi AppTec Co., Ltd. Class A and Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class A, occupying 9.96% and 9.94% of the portfolio correspondingly.
516060 assets under management is 95.84 M CNY. It's fallen 0.06% over the last month.
516060 fund flows account for −53.12 M CNY (1 year). Many traders use this metric to get insight into investors' sentiment and evaluate whether it's time to buy or sell the fund.
No, 516060 doesn't pay dividends to its holders.
516060 shares are issued by ICBC Credit Suisse Asset Management Co., Ltd. under the brand ICBC. The ETF was launched on Feb 9, 2021, and its management style is Passive.
516060 expense ratio is 0.52% meaning you'd have to pay 0.52% of your investment to help manage the fund.
516060 follows the CSI Innovative Drug Industry Index - CNY - Benchmark TR Gross. ETFs usually track some benchmark seeking to replicate its performance and guide asset selection and objectives.
516060 invests in stocks.
516060 price has risen by 15.49% over the last month, and its yearly performance shows a 21.74% increase. See more dynamics on 516060 price chart.
NAV returns, another gauge of an ETF dynamics, have risen by 11.31% over the last month, showed a 14.78% increase in three-month performance and has increased by 24.32% in a year.
NAV returns, another gauge of an ETF dynamics, have risen by 11.31% over the last month, showed a 14.78% increase in three-month performance and has increased by 24.32% in a year.
516060 trades at a premium (0.14%) meaning the ETF is trading at a higher price than the calculated NAV.